Literature DB >> 20074276

Clinical Use of Interferon-gamma.

Catriona H T Miller1, Stephen G Maher, Howard A Young.   

Abstract

Interferon gamma (IFN-gamma), a pleotropic cytokine, has been shown to be important to the function of virtually all immune cells and both innate and adaptive immune responses. In 1986, early clinical trials of this cytokine began to evaluate its therapeutic potential. The initial studies focused on the tolerability and pharmacology of IFN-gamma and systematically determined its antitumor and anti-infection activities. In the 20-plus years since those first trials, IFN-gamma has been used in a wide variety of clinical indications, which are reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20074276      PMCID: PMC6574079          DOI: 10.1111/j.1749-6632.2009.05069.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  67 in total

1.  Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis.

Authors:  S Skurkovich; A Boiko; I Beliaeva; A Buglak; T Alekseeva; N Smirnova; O Kulakova; V Tchechonin; O Gurova; T Deomina; O O Favorova; B Skurkovic; E Gusev
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

2.  Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.

Authors:  Y A Sigidin; G V Loukina; B Skurkovich; S Skurkovich
Journal:  Scand J Rheumatol       Date:  2001       Impact factor: 3.641

3.  A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease.

Authors:  L A Riddell; A J Pinching; S Hill; T T Ng; E Arbe; G P Lapham; S Ash; R Hillman; S Tchamouroff; D W Denning; J M Parkin
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

4.  Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.

Authors:  R B Moss; Y P Hsu; L Olds
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

5.  IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production.

Authors:  P R Madyastha; S Yang; W L Ries; L L Key
Journal:  J Interferon Cytokine Res       Date:  2000-07       Impact factor: 2.607

6.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.

Authors:  R Ziesche; E Hofbauer; K Wittmann; V Petkov; L H Block
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

7.  Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.

Authors:  K Katayama; A Kasahara; Y Sasaki; T Kashiwagi; M Naito; M Masuzawa; M Katoh; H Yoshihara; T Kamada; T Mukuda; T Hijioka; M Hori; N Hayashi
Journal:  J Viral Hepat       Date:  2001-05       Impact factor: 3.728

8.  T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies.

Authors:  C K Chen; M Y Wu; K H Chao; H N Ho; B C Sheu; S C Huang
Journal:  J Formos Med Assoc       Date:  1999-01       Impact factor: 3.282

9.  The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.

Authors:  A N Theofilopoulos; S Koundouris; D H Kono; B R Lawson
Journal:  Arthritis Res       Date:  2001-02-14

10.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Authors:  G H Windbichler; H Hausmaninger; W Stummvoll; A H Graf; C Kainz; J Lahodny; U Denison; E Müller-Holzner; C Marth
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  102 in total

1.  Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro.

Authors:  Ulrike Carolin Müller-Quernheim; Lars Potthast; Joachim Müller-Quernheim; Gernot Zissel
Journal:  J Interferon Cytokine Res       Date:  2012-01-26       Impact factor: 2.607

2.  Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.

Authors:  Cong Ding; Li Li; Yi Zhang; Zhenyu Ji; Chenglong Zhang; Taotao Liang; Xun Guo; Xin Liu; Qiaozhen Kang
Journal:  Oncol Lett       Date:  2018-07-20       Impact factor: 2.967

3.  Functional haplotypes of Fc gamma (Fcγ) receptor (FcγRIIA and FcγRIIIB) predict risk to repeated episodes of severe malarial anemia and mortality in Kenyan children.

Authors:  Collins Ouma; Gregory C Davenport; Steven Garcia; Prakasha Kempaiah; Ateefa Chaudhary; Tom Were; Samuel B Anyona; Evans Raballah; Stephen N Konah; James B Hittner; John M Vulule; John M Ong'echa; Douglas J Perkins
Journal:  Hum Genet       Date:  2011-08-05       Impact factor: 4.132

4.  The DNA damage response induces IFN.

Authors:  Sabrina Brzostek-Racine; Chris Gordon; Sarah Van Scoy; Nancy C Reich
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

5.  NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Authors:  Roshan J Thapa; Peirong Chen; Mitchell Cheung; Shoko Nogusa; Jianming Pei; Suraj Peri; Joseph R Testa; Siddharth Balachandran
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

6.  Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Authors:  Satyendra C Tripathi; Haley L Peters; Ayumu Taguchi; Hiroyuki Katayama; Hong Wang; Amin Momin; Mohit Kumar Jolly; Muge Celiktas; Jaime Rodriguez-Canales; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Eshel Ben-Jacob; Herbert Levine; Jeffrey J Molldrem; Samir M Hanash; Edwin J Ostrin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

7.  Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1).

Authors:  Peiyuan Li; Qiang Du; Zongxian Cao; Zhong Guo; John Evankovich; Wei Yan; Ying Chang; Lifang Shao; Donna Beer Stolz; Allan Tsung; David A Geller
Journal:  Cancer Lett       Date:  2011-10-01       Impact factor: 8.679

Review 8.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

9.  Wedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein dephosphorylation.

Authors:  Zhimin Chen; Xiaoxiao Sun; Shensi Shen; Haohao Zhang; Xiuquan Ma; Jingli Liu; Shan Kuang; Qiang Yu
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

10.  An overview of cytokines and cytokine antagonists as therapeutic agents.

Authors:  Raymond P Donnelly; Howard A Young; Amy S Rosenberg
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.